Results 101 to 110 of about 43,902 (289)

Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting.

Bone, 2022
BACKGROUND The rebound effect after denosumab discontinuation is lessened with subsequent zoledronate therapy. However, it is unclear whether this mitigation is sufficient after long-term denosumab treatment.
J. Everts-Graber, S. Reichenbach, B. Gahl, H. Häuselmann, H. Ziswiler, U. Studer, Thomas Lehmann   +6 more
semanticscholar   +1 more source

Survival Outcomes in Breast Cancer Patients With Metastatic Bone Disease

World Journal of Surgery, EarlyView.
To evaluate the survival outcomes of breast cancer patients with metastatic bone disease and to assess whether these patients exhibit different prognoses compared to those with more extensive metastatic involvement. ABSTRACT Objective To evaluate the survival outcomes of breast cancer patients with metastatic bone disease and to assess whether these ...
Gerard J. Hill, Aisling Hegarty, Gavin P. Dowling, Sandra Hembrecht, Gordon R. Daly, Trudi Roche, Eithne Downey, Michael Allen, Colm Power, Nuala Healy, Leonie S. Young, Arnold D. K. Hill   +11 more
wiley   +1 more source

Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab

Case Reports in Medicine, 2015
Giant cell tumor (GCT) of bone is a generally benign, but often locally aggressive, neoplasm of bone, with a propensity for recurrence. Sarcomatous transformation is rare and typically occurs with a history of recurrences and radiation treatment ...
Cory Julian Broehm, Erika L. Garbrecht, Jeff Wood, Therese Bocklage   +3 more
doaj   +1 more source

Giant Cell Tumor of Bone: Documented Progression over 4 Years from Its Origin at the Metaphysis to the Articular Surface. [PDF]

, 2016
The exact location of origin for giant cell tumors of bone (GCTB) remains controversial, as lesions are not routinely imaged early but rather late when the tumor is large and clinically symptomatic.
Burke, Colin, Cho, Soo-Jin, Link, Thomas, Motamedi, Daria, O'Donnell, Richard J   +4 more
core   +4 more sources

Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report

Frontiers in Endocrinology, 2022
Background Refractory hypercalcemia is one of the major complications of parathyroid carcinoma. Case report An 84-year old female patient presented with an acute confusional state due to hypercalcemia.
A. Roukain, Heba Alwan, M. Bongiovanni, G. Sykiotis, P. Kopp   +4 more
semanticscholar   +1 more source

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts   +13 more
wiley   +1 more source

The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study

Scientific Reports
The present study aimed to compare clinical and radiological differences of ONFH patients who were treated with denosumab, and a control group. A total of 178 patients (272 hips) with symptomatic, nontraumatic ONFH were divided into a denosumab group (98
Jun-Ki Moon, Jinyong Park, Yisack Yoo, Jae Youn Yoon, Sunhyung Lee, Pil Whan Yoon   +5 more
doaj   +1 more source

Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients

International Journal of Endocrinology, 2020
Purpose. Denosumab is a monoclonal antibody that prevents the development of osteoclasts. The effect of denosumab in solid organ transplant recipients has been elucidated, but its effect in haematopoietic stem cell transplantation recipients has not been
Chaiho Jeong, Hee-Je Kim, Seok Lee, Moo Il Kang, Jeonghoon Ha   +4 more
doaj   +1 more source

Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy

Orthopaedic Surgery, 2023
Objective The osteoclastic bone resorption inhibitors might have positive effect in preventing femoral head collapse in patients with osteonecrosis of the femoral head (ONFH).
Bo Liu, Feng Gao, Xiaofei Xiu, Tao Wu, Zeming Liu, Bingshi Zhang, Sikai Liu, Yongtai Han   +7 more
doaj   +1 more source

Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study [PDF]

, 2021
Chiara Marocco, Giovanna Zimatore, Edoardo Mocini, Rachele Fornari, Giovanni Iolascon, Maria Chiara Gallotta, Viviana Maria Bimonte, Carlo Baldari, Andrea Lenzi, Silvia Migliaccio   +9 more
openalex   +1 more source